Aurobindo Pharma Limited has informed the Exchange about Acquisition
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma's US arm, Aurobindo Pharma USA Inc., has signed a definitive agreement to buy 100% of Lannett Company LLC, a US-based generic pharmaceutical maker founded in 1942 and headquartered in Trevose, Pennsylvania. The deal is valued at US$250 million (about ₹2,185 crore) in cash on a debt-free, cash-free basis, translating to a 0.82x sales multiple. Lannett reported revenue of around $300 million (TTM FY25: $306 mn) and specializes in complex generics, generic liquids, and non-opioid controlled substances, particularly ADHD treatments. The acquisition gives Aurobindo a 425,000 sq ft US manufacturing facility in Seymour, Indiana, with annual capacity of about 3.6 billion doses, currently running at only 40% utilization. The deal is expected to close in 8–12 months subject to US FTC approval and is projected to be EPS accretive by around ₹5 per share.
This is a strategic, EPS-accretive acquisition that strengthens Aurobindo's US manufacturing presence, adds a profitable complex generics and CDMO business, and provides significant excess capacity for future growth — likely viewed positively by investors, though the $250 million cash outflow and regulatory uncertainty are key watchpoints.